References
- Van Effelterre TP, Hogea C, Taylor SM. Projected impact of Cervarix(R) vaccination on oncogenic human papillomavirus infection and cervical cancer in the United Kingdom. Hum Vaccin Immunother 2016; 12:8–19; PMID:25984886; http://dx.doi.org/10.1080/21645515.2015.1054584
- Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner, SR, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301-14; PMID:19586656; http://dx.doi.org/10.1016/S0140-6736(09)61248-4
- Kjaer SK, Nygard M, Dillner J, Munk C, Marshall B, Hansen B, Sigurdardottir L, Hortlund M, Tryggvadottir L, Saah A. Long-Term Effectiveness and Safety af Gardasil™ in the Nordic Countries. European Res Organization Genital Infect Neoplasia February 4–7. 2015. OC 6–1. Available at http://www.eurogin.com/2015/images/pdf/eurogin-2015_abstracts_part_2.pdf (accessed 21 Dec 2015)
- Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, de Borba PC, Sanchez N, Zahaf T, Catteau G, Geeraerts B, Descamps D. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother 2014; 10:2147-62; PMID:25424918; http://dx.doi.org/10.4161/hv.29532
- Malagon T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, Brisson M. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:781-89; PMID:22920953; http://dx.doi.org/10.1016/S1473-3099(12)70187-1
- Saah A, Luxembourg A, Brown D. Addressing an unmet medical need using a 9-valent virus-like particle (VLP)-based HPV vaccine. European Res Organization Genital Infect Neoplasia 2015. February 4–7. MSS 7–5 (2015). Available at http://www.eurogin.com/2015/images/pdf/eurogin_2015_abstracts_part_1.pdf (accessed 21 Dec 2015)
- Kreimer AR, Struyf F, Rosario-Raymundo MR, Hildesheim A, Skinner SR, Wacholder S, Garland SM, Herrero R, David MP, Wheeler CM. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol 2015; 16:775-86; PMID:26071347; http://dx.doi.org/10.1016/S1470-2045(15)00047-9
- Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine 2010; 28:6858-67; PMID:20713101; http://dx.doi.org/10.1016/j.vaccine.2010.08.030
- Wheeler CM, Castellsague X, Garland SM, Szarewski A, Paavonen J, Naud P, Salmeron J, Chow SN, Apter D, Kitchener H, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13:100-10; PMID:22075170; http://dx.doi.org/10.1016/S1470-2045(11)70287-X
- Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsague X, Skinner SR, Apter D, Naud P, Salmeron J, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13:89-99; PMID:22075171; http://dx.doi.org/10.1016/S1470-2045(11)70286-8
- GlaxoSmithKline clinical study register. A phase IIb, blinded, multi-center, long-term follow-up study of the efficacy of candidate HPV-16/18 VLP vaccine in the prevention of HPV-16 and/or HPV-18 cervical infection in adolescent and young adult women in North America and Brazil vaccinated in primary study 580299/001. HPV-16/18 VLP vaccine: GlaxoSmithKline Biologicals' virus-like particle (VLP) vaccine against human papillomaviruses (HPV)16 and 18. http://download.gsk-clinicalstudyregister.com/files/20401.pdf (accessed 21 Dec 2015)
- GlaxoSmithKline clinical study register. Follow-up study to evaluate the long-term efficacy of a HPV vaccine (580299) in healthy young adult women in Brazil. HPV vaccine (580299) (HPV): GlaxoSmithKline (GSK) Biologicals' vaccine against human papillomaviruses 16 and 18. https://gsk.sylogent.com/files/20207.pdf (accessed 21 Dec 2015)